Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cohance LifesciencesBOM:543064 -0.07%87 Days Payable is 121.09 as of Mar. 2026, which is 88% above its 10-year median of 64.53. GuruFocus rates BOM:543064 with a GF Score™ of 87/100 and a GF Value™ of ₹695.81 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 927 Drug Manufacturers companies, Cohance Lifesciences ranks better than 66.77% on this metric.
The historical rank and industry rank for Cohance Lifesciences's Days Payable or its related term are showing as below:
BOM:543064'
s Days Payable Range Over the Past 10 Years
Min: 27.39 Med: 64.53 Max: 126.56
Current: 124.5
During the past 8 years, Cohance Lifesciences's highest Days Payable was 126.56. The lowest was 27.39. And the median was 64.53.
BOM:543064's Days Payable is ranked better than 66.77% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs BOM:543064: 124.50
Cohance Lifesciences's Days Payable
increased
from Mar. 2025 (24.40) to Mar. 2026 (121.09).
It may suggest that Cohance Lifesciencesdelayed paying its suppliers.
The historical data trend for Cohance Lifesciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cohance Lifesciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cohance Lifesciences (BOM:543064) has a Days Payable of 121.09 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cohance Lifesciences and its competitors. This is 88% above median its historical median of 64.53. Over the past decade, Cohance Lifesciences' Days Payable has ranged from 27.39 to 126.56. According to the industry distribution chart, Cohance Lifesciences ranks #308 out of 927 companies in the Drug Manufacturers industry, placing it in the top 33.2%.
Is Cohance Lifesciences' Days Payable too high?
Cohance Lifesciences' current Days Payable of 121.09 is 88% above median its 10-year median of 64.53. Over the past 10 years, this metric has ranged from a low of 27.39 to a high of 126.56. The Drug Manufacturers industry median Days Payable is 90.28. Cohance Lifesciences' value of 121.09 is 34.1% above this industry median. Based on the distribution chart, Cohance Lifesciences ranks #308 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cohance Lifesciences has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cohance Lifesciences ranks #308 out of 927 companies for Days Payable. This puts Cohance Lifesciences in the upper half of its industry. The industry median Days Payable is 90.28. Cohance Lifesciences' value of 121.09 is 34.1% above this benchmark. Historically, Cohance Lifesciences' own Days Payable has ranged from 27.39 to 126.56 over the past decade. While the company's 10-year median is 64.53 vs. the industry median of 90.28, Cohance Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cohance Lifesciences's current Days Payable of 121.09 is 34.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cohance Lifesciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cohance Lifesciences's current Days Payable is 121.09, which is 88% above median its own 10-year median of 64.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Possible Value Trap. The stock's GF Value™ is ₹695.81, compared to a current price of ₹425.40 — trading 38.9% below its estimated fair value. The current Days Payable is 121.09, which is 88% above median its 10-year median of 64.53 and 34.1% above the Drug Manufacturers industry median of 90.28. Cohance Lifesciences' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Days Payable is 121.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹425.40 is trading 38.9% below its estimated GF Value™ of ₹695.81.
GuruFocus considers Cohance Lifesciences to be Possible Value Trap.
Key valuation signals for BOM:543064:
Days Payable: 121.09 (88% above median its 10-year median of 64.53)
GF Value™: ₹695.81 vs. price of ₹425.40 (38.9% below fair value)
Industry Position: 34.1% above the Drug Manufacturers median (#308 of 927)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score
Get the complete analysis for BOM:543064
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
